 |
|
|
| |
Real-World Implications of the New AASLD/IDSA HCV "Test and Treat" Algorithm:
Focus on Cardiovascular Comedications in Hepatitis C Virus (HCV) Patients Receiving Direct-Acting Antivirals (DAAs
|
| |
| |
AASLD 2025 Nov 7-11 Wash DC
Dilip Makhija,1 Thomas Debray,2 Candido Hernández3
1Gilead Lifesciences, Parsippany, United States of America, 2Smart Data Analysis and Statistics, Utrecht, Netherlands, 3Gilead Sciences, S.L.U, Madrid, Spain
|
| |
|
|
|
|
|
